AIxBIO at SynBioBeta 2026
Using AI to Make Biology Programmable
At the intersection of biology, AI, and drug discovery, the next breakthroughs won’t come from working in silos — they’ll come from bridging worlds.
AIxBIO at SynBioBeta 2026 is where startups, pharma leaders, and technologists tackle the toughest bottlenecks in biomedicine. Think foundation models trained on DNA, RNA, and protein sequences. Multimodal architectures that connect atoms, cells, and tissues. Simulations that go beyond static structures to capture dynamics across space and time.
By applying the power of AI to make biology truly engineerable — scaling datasets, optimizing chemistries, and designing programmable therapeutics — we’re building the interoperable infrastructure for the next generation of medicines. From context-aware drug modalities to dynamic, living simulations, this is the global stage where biology becomes programmable.
Why AIxBIO Matters
Biology is complex — static snapshots can’t capture the reality of tissues and patients.
Data is scarce. AI is limited by the quality of biological datasets.
Translation is hard. Bench predictions often fail in the clinic.
Therapeutics need intelligence. The future is adaptive, programmable drugs.
Who you'll meet
AIxBIO unites the people driving the future of biology and medicine.
AI startup founders building breakthrough models, datasets, and infrastructure.
Big Pharma R&D executives scouting the next wave of AI innovation.
Biologists, engineers, and investors driving convergence across disciplines
What to expect
AIxBIO is more than talks — it’s an environment built for discovery, collaboration, and ideas.
Insights into how AI can become the backbone of drug discovery and development.
Collaborations that bridge discovery with development, startups with pharma, and code with cells.
A community redefining what’s possible when intelligence meets life.
